ZTS

Business Profile & Competitive Position

Zoetis Inc. operates under the Healthcare sector in the Drug Manufacturers – Specialty & Generic industry, but its business is specifically global animal health. The company discovers, develops, manufactures and commercializes medicines, vaccines, diagnostics, biodevices, genetic tests and precision-animal-health services. Its products address eight core species—dogs, cats and horses on the companion side, and cattle, swine, poultry, fish and sheep on the livestock side—and are sold across more than 100 countries through U.S. and International operating segments.

The financial footprint suggests a profitable, concentrated franchise rather than a broad commodity portfolio. Net margin is 27.5% and return on equity is 69.3%. A net margin above one-quarter of revenue points to pricing power and relatively stable demand for established veterinary products, while a ROE near 70% signals strong capital efficiency—though it can also reflect meaningful leverage, depending on the capital structure supporting it. The 10-K notes real concentration risk: in 2025, the Simparica/Simparica Trio line contributed roughly 16% of revenue and the Apoquel/Apoquel Chewable line roughly 12%; the top five product lines together accounted for approximately 42% of revenue. Companion animal products represented about 70% of total revenue, with livestock at roughly 29%. That mix means Zoetis is primarily a pet-health business with a meaningful, but smaller, livestock attached business.

Financial Posture

At the time of the snapshot, Zoetis carried a market capitalization of $31.2B and traded at a P/E ratio of 12.2. That multiple sits well below the premium often associated with high-growth human specialty pharma or biotech names, which may reflect animal-health sector dynamics, mature product cycles or broader market discounting. Profitability figures remain strong: the 27.5% net margin and 69.3% ROE are both well above what most diversified healthcare companies produce, underlining that the company converts sales into profit efficiently.

The equity also behaves defensively relative to the broader market, with a beta of 0.73. That lower beta is consistent with a non-discretionary aspect of companion-animal care and recurring vaccine/diagnostic demand; pet owners and producers do not necessarily stop spending on animal health immediately when economic growth softens. The current trading snapshot shows the stock at $74.32, an RSI of 46.8 and the 50-day EMA at $76.81—neutral momentum and a price slightly below the near-term moving average, but that is descriptive, not a directional call.

Strategic Priorities & Outlook

Zoetis’s most recent 10-K identifies several operational priorities that define management’s near-term focus. The first is continued investment in discovery and development of new chemical, biopharmaceutical and biological entities, plus product lifecycle innovation aimed at extending the commercial relevance of existing franchises. A second priority is vaccine development for emerging infectious diseases, pursued with what the company describes as a “first to know and fast to market” operating philosophy.

On the diagnostics front, Zoetis is integrating new AI-driven capabilities into its Vetscan Imagyst platform to expand point-of-care testing in veterinary clinics. Operationally, 2026 is the year the company plans to eliminate the one-month reporting lag for subsidiaries outside the U.S. and align fiscal-year calendars between U.S. and International segments, which should simplify consolidated reporting and may change quarter-to-quarter comparability for investors.

Revenue composition in 2025 was lopsided toward the U.S.: domestic revenue was $5,097M, or 54% of total revenue, while International revenue was $4,254M, or 45%. That geographic split, combined with the Oct. 31, 2024 divestiture of the medicated feed additive portfolio, certain water-soluble products and related assets, signals a company narrowing its portfolio toward core high-margin animal-health products and away from more commoditized livestock inputs.

Macro & Geopolitical Exposure

As a Drug Manufacturers – Specialty & Generic company in animal health, Zoetis sits at the intersection of several macro and geopolitical channels. Regulatory risk is central: veterinary pharmaceuticals and vaccines must be approved by the FDA and by counterpart agencies abroad, and changes in labeling, manufacturing or import rules can alter product availability or launch timing. Pricing pressure is also a theme, especially for companion-animal therapeutics, where veterinarians and pet owners are sensitive to out-of-pocket cost even if demand is relatively sticky.

Livestock exposure ties a portion of the business to protein markets and agricultural cycles. Cattle, swine and poultry health spending tends to follow herd sizes, feed costs and producer profitability, all of which move with commodity prices and weather patterns. With 45% of revenue coming from International operations, currency translation and cross-border trade policy are relevant: tariffs on active pharmaceutical ingredients, finished goods or biologics could affect margins, while a stronger U.S. dollar would reduce the dollar value of overseas sales. Supply-chain exposure to imported raw materials and contract manufacturing is likewise typical for the industry. Finally, animal-disease outbreaks—avian influenza, African swine fever and foot-and-mouth, among others—can create surges in vaccine demand but also depress livestock economics if herds are culled or export restrictions rise.

Recent Developments

The latest headlines around Zoetis are all portfolio and analytical in nature, with no company-specific operational news during this window. On Sept. 14, 2026, Defense World reported that Corient Private Wealth LP held $35.07M in Zoetis shares. On Sept. 10, 2026, Defense World published a critical analysis comparing Zoetis with Urogen Pharma. On Sept. 9, 2026, Finbold noted that “Big Short” investor Michael Burry had updated his portfolio for September; this was a headline that included ZTS, but it did not detail a specific position size or rationale. On the same day, Sept. 9, 2026, Defense World reported that HB Wealth Management LLC had boosted its Zoetis holdings. These items reflect institutional-positioning activity and third-party commentary rather than a change in Zoetis’s fundamentals or guidance.

Earnings Behavior & Post-Earnings Drift

Zoetis has delivered strong headline earnings consistency over the last eight reported quarters, beating the consensus estimate in seven of those eight quarters—an 88% beat rate—with an average earnings surprise of 3.9%. Yet the average five-day price move following those reports was -4.1%, classified as a downward drift. That divergence is the most important takeaway for anyone modeling post-earnings behavior around ZTS: a beat has not reliably translated into a sustained pop.

The four most recent quarters illustrate the pattern. On Aug. 6, 2026, Zoetis reported $1.87 EPS against an estimate of $1.85, a 1.1% beat; the stock fell 5.97% the next day and was down 1.85% over the following five sessions. On May 7, 2026, the company missed with $1.53 versus $1.60, a -4.4% surprise; the stock dropped 5.13% the next day and 13.55% over five days. On Feb. 12, 2026, a 5.7% beat on $1.48 versus $1.40 produced only a 0.8% next-day gain and a 2.5% gain over five days—the one recent exception. On Nov. 4, 2025, a 4.9% beat with $1.70 against $1.62 was met with a -3.19% one-day move and a -3.49% five-day drift.

The unofficial consensus for the next report, scheduled for Nov. 3, 2026 before the open, stands at $1.52 EPS. Given the historical record, investors heading into that print should distinguish between earnings quality and price reaction: Zoetis has typically cleared the published estimate, but the market’s real expectation appears to be embedded in forward guidance, product-line commentary and margin outlook rather than in the headline number alone.

For a deeper dive, look at the full institutional verdict for ZTS, which aggregates sell-side ratings, price-target ranges and revision trends beyond the summary metrics covered here.